Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Muscle Nerve. 2015 Dec 29;53(2):313–317. doi: 10.1002/mus.24947

Figure 1. Clinical improvement is associated with a decrease in the frequency of circulating Tfh and plasmablasts.

Figure 1

Clinical and immunological profiles (y-axis) were measured before immunosuppression (T1) and three timepoints post immunosuppression (x-axis). A) MMT scores improved and CK levels decreased with immunosuppressive therapy. B) PFC analysis was performed on PBMCs to identify circulating Tfh cells (CD4+CD45RA-CXCR5+) and plasmablasts (CD19+CD27+CD20-CD38+). Highly elevated percentages of Tfh and plasmablasts were present prior to therapy and decreased dramatically with immunosupppresion.